Clinical Trial Detail

NCT ID NCT03499353
Title Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pfizer
Indications

triple-receptor negative breast cancer

Therapies

Talazoparib

Age Groups: adult senior

No variant requirements are available.